Hiroaki Hayashi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma, Aspirin-Induced | 7 | 2023 | 204 | 2.320 |
Why?
|
Anti-Asthmatic Agents | 4 | 2019 | 572 | 0.900 |
Why?
|
Aspirin | 7 | 2023 | 3134 | 0.800 |
Why?
|
Dinoprostone | 2 | 2024 | 597 | 0.640 |
Why?
|
Anti-Allergic Agents | 1 | 2020 | 153 | 0.630 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2023 | 2270 | 0.600 |
Why?
|
Asthma | 13 | 2024 | 6266 | 0.580 |
Why?
|
Respiratory Mucosa | 2 | 2017 | 437 | 0.500 |
Why?
|
Dinoprost | 1 | 2015 | 139 | 0.500 |
Why?
|
Cyclooxygenase 2 | 1 | 2017 | 597 | 0.470 |
Why?
|
Sinusitis | 2 | 2023 | 997 | 0.460 |
Why?
|
Leukotrienes | 1 | 2015 | 232 | 0.460 |
Why?
|
Th1 Cells | 1 | 2017 | 1040 | 0.410 |
Why?
|
Multiple Chemical Sensitivity | 2 | 2024 | 7 | 0.390 |
Why?
|
Cysteine | 1 | 2015 | 896 | 0.360 |
Why?
|
Allergens | 1 | 2017 | 1436 | 0.330 |
Why?
|
Exhalation | 3 | 2017 | 185 | 0.270 |
Why?
|
Breath Tests | 3 | 2017 | 297 | 0.260 |
Why?
|
Bronchial Hyperreactivity | 2 | 2017 | 299 | 0.250 |
Why?
|
Smoking Cessation | 1 | 2017 | 2085 | 0.250 |
Why?
|
Acetylcholine | 2 | 2017 | 628 | 0.220 |
Why?
|
Nitric Oxide | 3 | 2017 | 2140 | 0.210 |
Why?
|
Leukotriene E4 | 2 | 2020 | 75 | 0.210 |
Why?
|
Churg-Strauss Syndrome | 1 | 2022 | 75 | 0.190 |
Why?
|
Prostaglandin D2 | 1 | 2020 | 108 | 0.170 |
Why?
|
Mast Cells | 2 | 2024 | 1405 | 0.160 |
Why?
|
Japan | 5 | 2024 | 1418 | 0.150 |
Why?
|
Forced Expiratory Volume | 2 | 2020 | 1828 | 0.150 |
Why?
|
Respiratory Hypersensitivity | 1 | 2019 | 271 | 0.140 |
Why?
|
Ifosfamide | 1 | 2017 | 233 | 0.140 |
Why?
|
Medicine, Kampo | 1 | 2017 | 4 | 0.140 |
Why?
|
Platelet Activation | 2 | 2023 | 643 | 0.140 |
Why?
|
Wood | 1 | 2017 | 94 | 0.130 |
Why?
|
Area Under Curve | 1 | 2020 | 1639 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2022 | 713 | 0.130 |
Why?
|
Basophils | 1 | 2017 | 407 | 0.120 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 550 | 0.110 |
Why?
|
Adrenal Cortex Hormones | 1 | 2023 | 1884 | 0.110 |
Why?
|
Respiratory Function Tests | 2 | 2017 | 1691 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 614 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2105 | 0.110 |
Why?
|
Histamine | 1 | 2015 | 496 | 0.110 |
Why?
|
Sleep Apnea Syndromes | 1 | 2021 | 982 | 0.110 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2017 | 454 | 0.100 |
Why?
|
Eosinophilia | 1 | 2017 | 554 | 0.100 |
Why?
|
Respiration Disorders | 1 | 2015 | 364 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1320 | 0.090 |
Why?
|
Middle Aged | 16 | 2021 | 223267 | 0.090 |
Why?
|
Water | 1 | 2017 | 1416 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2017 | 1791 | 0.090 |
Why?
|
Cesarean Section | 1 | 2018 | 1418 | 0.080 |
Why?
|
Female | 20 | 2024 | 396532 | 0.080 |
Why?
|
Mice, Knockout | 1 | 2024 | 14473 | 0.080 |
Why?
|
Humans | 25 | 2024 | 766812 | 0.070 |
Why?
|
Lung | 2 | 2024 | 10068 | 0.070 |
Why?
|
Adult | 11 | 2021 | 223305 | 0.070 |
Why?
|
Male | 17 | 2024 | 364154 | 0.070 |
Why?
|
Mucus | 1 | 2008 | 346 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2020 | 12430 | 0.060 |
Why?
|
Mucins | 1 | 2008 | 569 | 0.060 |
Why?
|
Receptors, Prostaglandin E, EP2 Subtype | 1 | 2024 | 48 | 0.060 |
Why?
|
Receptors, Thromboxane | 1 | 2023 | 30 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15912 | 0.050 |
Why?
|
Aged | 8 | 2020 | 171344 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7585 | 0.050 |
Why?
|
Membrane Transport Proteins | 1 | 2008 | 1029 | 0.050 |
Why?
|
Risk Factors | 5 | 2019 | 74889 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2023 | 81657 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12246 | 0.040 |
Why?
|
Peak Expiratory Flow Rate | 1 | 2019 | 143 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 59939 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 70 | 0.040 |
Why?
|
Amino Acids | 1 | 2024 | 1711 | 0.040 |
Why?
|
Amylases | 1 | 2017 | 171 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 3246 | 0.040 |
Why?
|
Feces | 1 | 2024 | 1505 | 0.030 |
Why?
|
Blood Platelets | 2 | 2019 | 2465 | 0.030 |
Why?
|
Pyrophosphatases | 1 | 2017 | 142 | 0.030 |
Why?
|
Trehalose | 1 | 2017 | 88 | 0.030 |
Why?
|
Odds Ratio | 2 | 2018 | 9661 | 0.030 |
Why?
|
Medical Futility | 1 | 2017 | 136 | 0.030 |
Why?
|
Vital Capacity | 1 | 2019 | 995 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 13090 | 0.030 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2017 | 205 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2019 | 513 | 0.030 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 2015 | 115 | 0.030 |
Why?
|
Causality | 1 | 2021 | 1252 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2017 | 592 | 0.030 |
Why?
|
Waist Circumference | 1 | 2018 | 934 | 0.030 |
Why?
|
Inflammation | 2 | 2024 | 10863 | 0.030 |
Why?
|
Comorbidity | 2 | 2021 | 10580 | 0.030 |
Why?
|
Nasal Polyps | 1 | 2019 | 412 | 0.030 |
Why?
|
Pets | 1 | 2013 | 46 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13489 | 0.030 |
Why?
|
Pneumonia | 1 | 2024 | 2161 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 65286 | 0.020 |
Why?
|
Age of Onset | 1 | 2019 | 3343 | 0.020 |
Why?
|
Cats | 1 | 2013 | 972 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2606 | 0.020 |
Why?
|
Bronchi | 1 | 2015 | 847 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 1189 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1867 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36570 | 0.020 |
Why?
|
Mice | 3 | 2024 | 81898 | 0.020 |
Why?
|
Dogs | 1 | 2013 | 3834 | 0.020 |
Why?
|
Mucin 5AC | 1 | 2008 | 96 | 0.020 |
Why?
|
Rabbits | 1 | 2013 | 4752 | 0.020 |
Why?
|
Animals | 4 | 2024 | 168939 | 0.020 |
Why?
|
COS Cells | 1 | 2008 | 1135 | 0.020 |
Why?
|
Interleukin-13 | 1 | 2008 | 391 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22351 | 0.020 |
Why?
|
Neutrophil Infiltration | 1 | 2008 | 392 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10101 | 0.010 |
Why?
|
Patient Compliance | 1 | 2013 | 2694 | 0.010 |
Why?
|
Th2 Cells | 1 | 2008 | 1077 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23618 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2018 | 22248 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 13050 | 0.010 |
Why?
|
Heart Diseases | 1 | 2013 | 2817 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9407 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 54872 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20146 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26309 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40149 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11876 | 0.010 |
Why?
|
Age Factors | 1 | 2013 | 18397 | 0.010 |
Why?
|
Smoking | 1 | 2013 | 9077 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2008 | 3698 | 0.010 |
Why?
|
Neutrophils | 1 | 2008 | 3782 | 0.010 |
Why?
|
Genome, Human | 1 | 2008 | 4443 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5888 | 0.010 |
Why?
|
Hospitalization | 1 | 2013 | 10816 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8616 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2008 | 18329 | 0.000 |
Why?
|